INCY 71.68 Incyte Corp $INCY Hit a 52 week high of 72.36 Closing the day 09:45 at 71.68 -0.19 -0.26% With a day low of 71.60 and a total volume of 50,810.
INCY Recent Posts: http://investorshangout.com/Incyte-Corporation-INCY-54453/
INCY Incyte Corp Recent Headline News
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.72 (+0.41), INCY: 71.61 (-0.26), CLDX: 14.55 (-0.26), NLNK: 31.34 (-1.05), GSK: 45.66 (+0.04), BMY: 57.82 (-0.79), SRNE: 4.27 (-0.17)
Watch for Incyte to Potentially Pullback After Gaining 2.37% Yesterday
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.61 (-0.26)
SmarTrend Watching for Potential Pullback in Shares of Incyte After 2.37% Gain
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.61 (-0.26)
Incyte Earnings Review: 11 Days after Announcement Shares Up 8.0% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 1:34PM CST
A week ago on October 30th, 2014 Incyte (NASDAQ:INCY) reported earnings and analysts, on average, expected earnings of $0.09 on sales of $149.9 million. Incyte actually reported earnings of $0.33 per share on sales of $198.1 million, beating EPS estimates by $0.24 and beating revenue estimates by $48.3 million. Shares of Incyte have climbed from $64.18 to $69.32, representing a gain of 8.0% since the company reported earnings 11 days ago.
INCY: 71.61 (-0.26)
Uptrend Call Working As Incyte Stock Rises 35.6% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 10:48AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 3 weeks, Incyte has returned 35.57% as of today's recent price of $69.25.
INCY: 71.61 (-0.26)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.41 (+0.22), PCYC: 138.17 (+0.80), CLDX: 14.55 (-0.26), INCY: 71.61 (-0.26), BIND: 10.18 (+0.20), CELG: 107.13 (-1.12), OMER: 19.26 (-0.45), VSTM: 9.33 (-0.04), GILD: 104.21 (-2.69), OGXI: 2.13 (-0.05), ANTH: 1.84 (+0.02), NVAX: 5.27 (+0.03)
After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 2.37 (unch), INCY: 71.61 (-0.26)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.45 (+0.03), INCY: 71.61 (-0.26), ONTX: 4.82 (-0.03), BMY: 57.82 (-0.79), GSK: 45.66 (+0.04), STML: 14.66 (-0.40), SNTA: 3.31 (-0.05), KBIO: 2.10 (-0.01), BPTH: 2.97 (+0.02), CELGZ: 3.14 (+0.01), NVS: 94.36 (+1.70)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.37 (-0.04), BCR: 165.84 (+0.63), INCY: 71.61 (-0.26), MYL: 55.45 (+1.65), AEGR: 20.64 (-0.67)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 101.67 (+1.82), CYTX: 0.46 (+0.08), ACHN: 13.81 (-1.04), INCY: 71.61 (-0.26), SRPT: 15.29 (-0.24)
30.9% Return Seen to Date on SmarTrend Incyte Call (INCY)
Comtex SmarTrend(R) - Mon Nov 03, 9:21AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 weeks, Incyte has returned 30.87% as of today's recent price of $66.85.
INCY: 71.61 (-0.26)
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 317.37 (-3.65), INCY: 71.61 (-0.26), LLY: 67.78 (+0.38), NVS: 94.36 (+1.70)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 106.27 (-0.06), BIIB: 317.37 (-3.65), INCY: 71.61 (-0.26), ILMN: 187.29 (+0.37)
Upgrade Alert for Incyte (INCY)
Comtex SmarTrend(R) - Fri Oct 31, 6:57AM CDT
Incyte (NASDAQ:INCY) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $64.18 on volume of 2.5 million shares, above average daily volume of 1.1 million. Potential upside of 22.5% exists for Incyte, based on a current level of $64.18 and analysts' average consensus price target of $78.64. Incyte shares have support at the 200-day moving average (MA) of $53.86 and additional support at the 50-day MA of $50.86.
INCY: 71.61 (-0.26)
Incyte ups Jakafi sales guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:13PM CDT
INCY: 71.61 (-0.26)
Incyte's (INCY) CEO Hervé Hoppenot on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:40PM CDT
INCY: 71.61 (-0.26)
Incyte (INCY) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 7:25AM CDT
INCY: 71.61 (-0.26)
Incyte beats by $0.33, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:18AM CDT
INCY: 71.61 (-0.26)
Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Business Wire - Thu Oct 30, 6:01AM CDT
--2014 guidance for Jakafi net product revenues increased to range of $350 million to $360 million, driven by continued strong growth in underlying demand
INCY: 71.61 (-0.26), NVS: 94.36 (+1.70)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:30PM CDT
FIS: 59.00 (+0.09), HST: 22.68 (unch), CRR: 48.33 (-2.19), CAH: 80.77 (+0.53), AMT: 100.22 (+0.48), ACIW: 18.75 (+0.23), GTI: 4.23 (-0.14), IDA: 61.67 (-0.40), CRCM: 8.64 (-0.75), CVRR: 23.15 (-0.21), BGCP: 8.55 (-0.10), GOV: 23.13 (+0.18), DFT: 31.45 (+0.16), APO: 22.92 (+0.35), FIG: 7.52 (+0.10), AMAG: 34.78 (-0.15), HAR: 105.68 (-2.13), AVP: 10.44 (-0.14), EXLS: 28.75 (-0.17), INGR: 79.77 (-0.33), ALU: 3.05 (-0.13), INCY: 71.61 (-0.26), COP: 70.29 (-0.91), GEL: 48.35 (+0.03), COR: 38.47 (+0.26), GTLS: 44.12 (-2.13), BWA: 55.46 (+0.21), CARB: 11.47 (+0.06), GLOP: 24.66 (-0.31), IDCC: 50.06 (-0.59), HEES: 37.37 (-0.83), BCO: 21.38 (-0.19), DST: 99.09 (+0.23), EPD: 38.01 (+0.21), ABMD: 33.36 (-0.24), CEVA: 15.90 (-0.12), BLL: 65.39 (-0.16), GBX: 64.12 (+1.67), GNC: 43.57 (-0.65), CVI: 47.35 (-0.67), ACOR: 34.51 (-0.39), I: 18.00 (+0.23), FCN: 41.17 (+0.16), CRNT: 1.17 (+0.02), DHX: 11.26 (+0.07), BG: 88.58 (+0.07), CME: 85.45 (-0.15), FCH: 10.62 (+0.01), ALLE: 52.24 (-0.26), AUDC: 4.69 (-0.09), APD: 135.11 (+0.32), DBD: 35.04 (-0.63), HGG: 6.05 (+0.15), CBM: 23.60 (-0.42), CNSL: 27.05 (+0.13), ATK: 111.50 (-0.44), ANR: 2.43 (-0.19), CI: 102.92 (+0.81), ABC: 89.10 (+0.39), GG: 19.78 (+0.11)
INCY Recent Posts: http://investorshangout.com/Incyte-Corporation-INCY-54453/
INCY Incyte Corp Recent Headline News
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.72 (+0.41), INCY: 71.61 (-0.26), CLDX: 14.55 (-0.26), NLNK: 31.34 (-1.05), GSK: 45.66 (+0.04), BMY: 57.82 (-0.79), SRNE: 4.27 (-0.17)
Watch for Incyte to Potentially Pullback After Gaining 2.37% Yesterday
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.61 (-0.26)
SmarTrend Watching for Potential Pullback in Shares of Incyte After 2.37% Gain
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.61 (-0.26)
Incyte Earnings Review: 11 Days after Announcement Shares Up 8.0% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 1:34PM CST
A week ago on October 30th, 2014 Incyte (NASDAQ:INCY) reported earnings and analysts, on average, expected earnings of $0.09 on sales of $149.9 million. Incyte actually reported earnings of $0.33 per share on sales of $198.1 million, beating EPS estimates by $0.24 and beating revenue estimates by $48.3 million. Shares of Incyte have climbed from $64.18 to $69.32, representing a gain of 8.0% since the company reported earnings 11 days ago.
INCY: 71.61 (-0.26)
Uptrend Call Working As Incyte Stock Rises 35.6% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 10:48AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 3 weeks, Incyte has returned 35.57% as of today's recent price of $69.25.
INCY: 71.61 (-0.26)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.41 (+0.22), PCYC: 138.17 (+0.80), CLDX: 14.55 (-0.26), INCY: 71.61 (-0.26), BIND: 10.18 (+0.20), CELG: 107.13 (-1.12), OMER: 19.26 (-0.45), VSTM: 9.33 (-0.04), GILD: 104.21 (-2.69), OGXI: 2.13 (-0.05), ANTH: 1.84 (+0.02), NVAX: 5.27 (+0.03)
After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 2.37 (unch), INCY: 71.61 (-0.26)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.45 (+0.03), INCY: 71.61 (-0.26), ONTX: 4.82 (-0.03), BMY: 57.82 (-0.79), GSK: 45.66 (+0.04), STML: 14.66 (-0.40), SNTA: 3.31 (-0.05), KBIO: 2.10 (-0.01), BPTH: 2.97 (+0.02), CELGZ: 3.14 (+0.01), NVS: 94.36 (+1.70)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.37 (-0.04), BCR: 165.84 (+0.63), INCY: 71.61 (-0.26), MYL: 55.45 (+1.65), AEGR: 20.64 (-0.67)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 101.67 (+1.82), CYTX: 0.46 (+0.08), ACHN: 13.81 (-1.04), INCY: 71.61 (-0.26), SRPT: 15.29 (-0.24)
30.9% Return Seen to Date on SmarTrend Incyte Call (INCY)
Comtex SmarTrend(R) - Mon Nov 03, 9:21AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 weeks, Incyte has returned 30.87% as of today's recent price of $66.85.
INCY: 71.61 (-0.26)
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 317.37 (-3.65), INCY: 71.61 (-0.26), LLY: 67.78 (+0.38), NVS: 94.36 (+1.70)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 106.27 (-0.06), BIIB: 317.37 (-3.65), INCY: 71.61 (-0.26), ILMN: 187.29 (+0.37)
Upgrade Alert for Incyte (INCY)
Comtex SmarTrend(R) - Fri Oct 31, 6:57AM CDT
Incyte (NASDAQ:INCY) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $64.18 on volume of 2.5 million shares, above average daily volume of 1.1 million. Potential upside of 22.5% exists for Incyte, based on a current level of $64.18 and analysts' average consensus price target of $78.64. Incyte shares have support at the 200-day moving average (MA) of $53.86 and additional support at the 50-day MA of $50.86.
INCY: 71.61 (-0.26)
Incyte ups Jakafi sales guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:13PM CDT
INCY: 71.61 (-0.26)
Incyte's (INCY) CEO Hervé Hoppenot on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:40PM CDT
INCY: 71.61 (-0.26)
Incyte (INCY) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 7:25AM CDT
INCY: 71.61 (-0.26)
Incyte beats by $0.33, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:18AM CDT
INCY: 71.61 (-0.26)
Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Business Wire - Thu Oct 30, 6:01AM CDT
--2014 guidance for Jakafi net product revenues increased to range of $350 million to $360 million, driven by continued strong growth in underlying demand
INCY: 71.61 (-0.26), NVS: 94.36 (+1.70)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:30PM CDT
FIS: 59.00 (+0.09), HST: 22.68 (unch), CRR: 48.33 (-2.19), CAH: 80.77 (+0.53), AMT: 100.22 (+0.48), ACIW: 18.75 (+0.23), GTI: 4.23 (-0.14), IDA: 61.67 (-0.40), CRCM: 8.64 (-0.75), CVRR: 23.15 (-0.21), BGCP: 8.55 (-0.10), GOV: 23.13 (+0.18), DFT: 31.45 (+0.16), APO: 22.92 (+0.35), FIG: 7.52 (+0.10), AMAG: 34.78 (-0.15), HAR: 105.68 (-2.13), AVP: 10.44 (-0.14), EXLS: 28.75 (-0.17), INGR: 79.77 (-0.33), ALU: 3.05 (-0.13), INCY: 71.61 (-0.26), COP: 70.29 (-0.91), GEL: 48.35 (+0.03), COR: 38.47 (+0.26), GTLS: 44.12 (-2.13), BWA: 55.46 (+0.21), CARB: 11.47 (+0.06), GLOP: 24.66 (-0.31), IDCC: 50.06 (-0.59), HEES: 37.37 (-0.83), BCO: 21.38 (-0.19), DST: 99.09 (+0.23), EPD: 38.01 (+0.21), ABMD: 33.36 (-0.24), CEVA: 15.90 (-0.12), BLL: 65.39 (-0.16), GBX: 64.12 (+1.67), GNC: 43.57 (-0.65), CVI: 47.35 (-0.67), ACOR: 34.51 (-0.39), I: 18.00 (+0.23), FCN: 41.17 (+0.16), CRNT: 1.17 (+0.02), DHX: 11.26 (+0.07), BG: 88.58 (+0.07), CME: 85.45 (-0.15), FCH: 10.62 (+0.01), ALLE: 52.24 (-0.26), AUDC: 4.69 (-0.09), APD: 135.11 (+0.32), DBD: 35.04 (-0.63), HGG: 6.05 (+0.15), CBM: 23.60 (-0.42), CNSL: 27.05 (+0.13), ATK: 111.50 (-0.44), ANR: 2.43 (-0.19), CI: 102.92 (+0.81), ABC: 89.10 (+0.39), GG: 19.78 (+0.11)
